Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON38693
NL-OMON38693CompletedNot Applicable

DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING DOSES AND THE EFFECT OF FOOD ON ORAL WCK 4873 IN HEALTHY ADULT VOLUNTEERS - WCK 4873 Phase 1 SAD FE Study

Wockhardt Bio AG0 sites78 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
78
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •healthy male or female
  • •18 - 65 years inclusive
  • •BMI 18.0 - 30.0 kg/m2 inclusive
  • •non-smoker

Exclusion Criteria

  • •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS.
  • •Participation in another drug study within 60 days prior to randomization.
  • •Any donation of blood(products) or significant blood loss within 60 days prior to drug administration

Investigators

Similar Trials

Completed
Not Applicable
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, IN PARALLEL GROUPS, MULTICENTER, TO EVALUATE EFFICACY AND SAFETY IN TREATMENT REPEATED WITH TEGASEROD 6 MG TWICE PER DAY AND PLACEBO IN WOMEN WITH IRRITABLE BOWEL SYNDROME CO
PER-076-02OVARTIS BIOSCIENSES PERU S.A.,
Completed
Not Applicable
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)-A41 Other sepsisOther sepsisA41
PER-017-04ELI LILLY INTERAMERICA INC.,
Completed
Not Applicable
PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF AERUCIN® ASADJUNCT THERAPY TO ANTIBIOTICS IN THE TREATMENT OF P. AERUGINOSAPNEUMONIA-J151 Pneumonia due to PseudomonasPneumonia due to PseudomonasJ151
PER-019-18Aridis Pharmaceuticals, Inc,
Completed
Phase 3
RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE, EFFICACY, SAFETY AND TOLERABILITY OF EPA-FFA GASTRO-RESISTANT CAPSULES, IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)FAPhereditary development of polyps in colon1001801810017991
NL-OMON55587SLA Pharma30
Active, not recruiting
Not Applicable
A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S)COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITHETANERCEPT PLUS DMARD(S)Rheumatoid Arthritis
EUCTR2011-005448-87-HUPfizer Inc, 235 East 42nd Street, New York, NY 10017320